Serum amyloid A (SAA) is an apo-lipoprotein produced by the liver in response to proinflammatory cytokines. Few data are available on SAA levels in patients with idiopathic pulmonary fibrosis (IPF), the most common idiopathic form of interstitial pneumonitis (ILD). This study compared SAA concentration in IPF patients to other ILD groups to explore its potential use as a clinical biomarker.
Vietri, L., D'Alessandro, M., Bergantini, L., Carleo, A., Cameli, P., Mazzei, M.A., et al. (2020). Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis. INTERNAL MEDICINE JOURNAL, 50(12), 1571-1574 [10.1111/imj.15113].
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis
d'Alessandro M.;Bergantini L.;Cameli P.;Mazzei M. A.;Sestini P.;Bargagli E.
2020-01-01
Abstract
Serum amyloid A (SAA) is an apo-lipoprotein produced by the liver in response to proinflammatory cytokines. Few data are available on SAA levels in patients with idiopathic pulmonary fibrosis (IPF), the most common idiopathic form of interstitial pneumonitis (ILD). This study compared SAA concentration in IPF patients to other ILD groups to explore its potential use as a clinical biomarker.
| File | Dimensione | Formato | |
|---|---|---|---|
|
saa ipf.pdf
non disponibili
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
507.39 kB
Formato
Adobe PDF
|
507.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1128661